An interventional study of Soft exosuit and No Soft exosuit in Stroke, sponsored by Boston University Charles River Campus. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 1,330th largest by enrollment of the 1,621 interventional ones that give a count, is one of 115 that started in 2021, is one of 1,124 with no phase, and was the 1,430th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 115 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,332 that completed or were terminated, 564 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
Boston University Charles River Campus is the lead sponsor of 160 studies on the registry; 34 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Boston University Charles River Campus has 7 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
167 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 167 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
High intensity exercise is known to improve a person's ability to learn new motor skills. The goal of this project is to evaluate if a robotic exosuit can help people who have had a stroke perform walking rehabilitation at higher intensities than they are able to without the exosuit. The investigators will measure exercise training intensity, biomarkers of neuroplasticity (e.g., brain-derived neurotrophic factor; BDNF), and motor learning when people poststroke exercise with and without the exosuit. For this protocol, exosuits developed in collaboration with ReWalk™ Robotics will be used.
Aim 1: Determine the effects of a soft robotic exosuit on gait training intensity and serum BDNF in persons post-stroke completing a single bout of high intensity walking.
Hypothesis 1: Exosuits will allow individuals post-stroke to (i) walk at higher intensities or (ii) walk at a high intensity for longer durations.
Hypothesis 2: Training at a higher intensity, or training at high intensity for longer durations, will result in increased serum BDNF.
Aim 2: Determine the effects of a soft robotic exosuit on gait biomechanics measured after a single bout of high intensity walking with versus without a soft robotic exosuit.
Hypothesis 3: A single bout of high intensity walking with an exosuit will lead to demonstrably better gait biomechanics than a single bout of high intensity exercise without an exosuit.
Prior studies of the exosuit technology have culminated in strong evidence for the gait-restorative effects of soft robotic exosuits for patients post-stroke by means of substitution for impaired paretic limb function during walking. The present study builds on this work by suggesting that an exosuit's immediate gait-restorative effects can be leveraged during high intensity gait training to produce post-training improvements in gait quality. Indeed, current rehabilitation efforts are focused on either quality or intensity. They focus on gait quality by reducing the training intensity to allow patients to achieve a more normal gait. In contrast, efforts focused on training intensity push participants without regard for the quality of their movements. The investigators posit that exosuits can uniquely enable high intensity gait training that promotes quality of movements.
Acute bouts of high intensity exercise prior to skilled task practice have been shown to enhance motor learning in neurologically intact individuals. However, the impact of high intensity exercise on motor learning in clinical populations remains largely unknown. A major limitation to studying this relationship in survivors of stroke are challenges in achieving and maintaining high intensity exercise levels (>75% max HR) during gait training for durations that are comparable to neurologically intact individuals. Exercising at a lower intensity or for a shorter duration may result in insufficient neurological "priming" for motor learning that typically follows high intensity training-which would be evidenced in reduced production of activity-dependent markers of neuroplasticity (e.g., brain-derived neurotrophic factor; BDNF). For this study, the investigators will use standardized, maximal effort tests to evaluate the ability of a soft robotic exosuit to increase a patient's capacity for high intensity gait training. The investigators will also examine the resulting effect on BDNF and the relationship between training intensity, BDNF and motor learning measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnancy
Note: If the study team suspects neglect or hemianopia at any time during the course of the research, the physical therapist may administer the Star Cancellation Test (https://www.strokengine.ca/en/assess/sct/) for neglect or a visual field test (e.g., showing visual stimuli on different sides of the body) for hemianopia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants do progressive cardiovascular exercise testing on a treadmill with soft exosuit assistance. Following a wash out period of 1-2 weeks, progressive cardiovascular exercise testing on a treadmill is done without exosuit assistance.
Device: Soft exosuit · Behavioral: No Soft exosuit
Participants do progressive cardiovascular exercise testing on a treadmill without exosuit assistance. Following a wash out period of 1-2 weeks, progressive cardiovascular exercise testing on a treadmill is done with exosuit assistance.
Device: Soft exosuit · Behavioral: No Soft exosuit
Progressive cardiovascular exercise testing with soft exosuit assistance, a textile based exosuit that provides mechanical assistance to the paretic plantarflexors and dorsiflexors during walking.
Progressive cardiovascular exercise testing.
VO2-Peak
Average peak oxygen consumption rate.
Time frame: Last 30 seconds of maximal effort exercise test.
Duration of High Intensity Exercise
Minutes spent exercising at greater than or equal to 76% age-predicted heart rate maximum value.
Time frame: From the beginning to the end of the test, as determined based on standardized test termination criteria (e.g., volitional fatigue, cardiovascular abnormalities, or physical safety)
Concentration of Brain-derived Neurotrophic Factor (BDNF)
A neurotrophic factor that is essential for learning and memory.
Time frame: Baseline.
Concentration of Brain-derived Neurotrophic Factor (BDNF)
A neurotrophic factor that is essential for learning and memory.
Time frame: Immediately after maximal effort exercise test.
Propulsion Symmetry
Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.
Time frame: Baseline.
Propulsion Symmetry
Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.
Time frame: Immediately after maximal effort exercise test.
| Milestone | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit |
|---|---|---|
| Started | 4 | 7 |
| Completed | 4 | 7 |
| Not completed | 0 | 0 |
| Milestone | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit |
|---|---|---|
| Started | 4 | 7 |
| Completed | 4 | 7 |
| Not completed | 0 | 0 |
| Milestone | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit |
|---|---|---|
| Started | 4 | 7 |
| Completed | 4 | 7 |
| Not completed | 0 | 0 |
Average peak oxygen consumption rate.
| ml O2/kg/min | Exosuit | No Exosuit |
|---|---|---|
| VO2-Peak | 18.83 ± 1.65 | 17.08 ± 1.50 |
Minutes spent exercising at greater than or equal to 76% age-predicted heart rate maximum value.
| Minutes | Exosuit | No Exosuit |
|---|---|---|
| Duration of High Intensity Exercise | 12.45 ± 1.41 | 10.39 ± 1.36 |
A neurotrophic factor that is essential for learning and memory.
| ng/ml | Exosuit | No Exosuit |
|---|---|---|
| Concentration of Brain-derived Neurotrophic Factor (BDNF) | 40.96 ± 3.28 | 45.15 ± 3.78 |
A neurotrophic factor that is essential for learning and memory.
| ng/ml | Exosuit | No Exosuit |
|---|---|---|
| Concentration of Brain-derived Neurotrophic Factor (BDNF) | 46.92 ± 3.96 | 48.49 ± 3.67 |
Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.
| Percentage | Exosuit | No Exosuit |
|---|---|---|
| Propulsion Symmetry | 31 ± 2 | 35 ± 2 |
Propulsion symmetry was computed as the paretic-limb peak propulsion divided by the sum of paretic- and non-paretic-limb peak propulsion, with peaks taken from the mass-normalized anterior ground reaction force of each limb. Values approaching 50% indicate greater interlimb symmetry. This measure was used to evaluate training-induced changes in gait symmetry within each condition.
| Percentage | Exosuit | No Exosuit |
|---|---|---|
| Propulsion Symmetry | 30 ± 3 | 33 ± 2 |
Collected over From Day 1 to Day 2, separated by a washout period of 1-2 weeks, with a total of up to 3 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exosuit | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| No Exosuit | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Event | Exosuit | No Exosuit |
|---|---|---|
| A decrease in heart rate and abnormal blood pressure.General disorders | 0/11 | 1/11 |
| Age, Continuous(years) | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit | Total |
|---|---|---|---|
| Mean | 55 ± 16 | 59 ± 12 | 58 ± 13 |
| Sex: Female, Male(Participants) | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 3 | 5 | 8 |
| Race and Ethnicity Not Collected(Participants) | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | No-Exosuit Then Exosuit | Exosuit Then No-Exosuit | Total |
|---|---|---|---|
| United States | 4 | 7 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Aug 2022, 13 months.
Results were first posted in Nov 2026, 4 years 2 months after primary completion.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 13 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston University Charles River Campus →